clinical trials articles ↓

A trial seeking participants interested in being treated with topically disolved oxygen (TDO) has been posted to clinicaltrials.gov. Aria Aesthetics is listed as supplying the `Aria Regimens’ in 0.5%, and 0.25%. As the trial is double blind and placebo controlled, a third group will receive no TDO during their treatments. Zoe Draelos MD is listed as a contact for the trial. Dr. Draelos …

A new trial is recruiting participants to evaluate the use of calcium dobelisate as a combination therapy, along with Pulse Dye Laser to treat the erythema, flushing and telangectasia associated with erythematotelangietatic rosacea. We know from rosacea and doxium that “Calcium dobesilate is a vasoactive drug with presumed effects on endothelial integrity, capillary permeability and blood viscosity.” Clinical Trial …

An intriguing Clinical Trial has been listed on the ClinicalTrials.gov web site. The product know only as DER 45 EV Gel (in strengths of 1% and 5%) has been listed in a dose-range trial for the papules and pustules of rosacea. Clinical Trial NCT00940992, A Dose-Range of DER 45-EV in Treatment of Rosacea (SGT-EBPO1-09) …

Thanks to a comment from Sophie on the post rosacea and doxium (calcium dobesilate) we know that Dr. Cuevas who is responsible for several papers on Dobesilate, is accepting people to try it as a treatment for rosacea. Thanks for the info Sophie. Calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a vasoactive drug with presumed effects on endothelial integrity, capillary permeability and blood viscosity. It …

The Clinical Trials register has listed a new trial for papulopustular rosacea. The trial, sponsored by Intendis, the manufacturer of Finacea, wants to compare the combination of Oracea and Finacea, with the combination of Oracea and Metrogel 1%.

It seems clear from this that Intendis would like to position Finacea as a viable …